ProShares Ultra Nasdaq Biotechnology (BIB)

NASDAQ: BIB · IEX Real-Time Price · USD
61.35
-2.70 (-4.22%)
At close: Dec 5, 2022 1:56 PM
61.29
-0.06 (-0.10%)
After-hours: Dec 5, 2022 4:15 PM EST
-4.22%
Assets $113.39M
NAV $61.29
Expense Ratio 0.95%
PE Ratio n/a
Shares Out 1.85M
Dividend (ttm) n/a
Dividend Yield n/a
Ex-Dividend Date Dec 22, 2022
1-Year Return -19.32%
Volume 27,195
Open 63.39
Previous Close 64.05
Day's Range 60.66 - 63.56
52-Week Low 38.42
52-Week High 85.18
Beta 1.61
Holdings 370
Inception Date Apr 8, 2010

About BIB

The ProShares Ultra Nasdaq Biotechnology (BIB) is an exchange-traded fund that is based on the NASDAQ / Biotechnology index. The fund provides 2x daily exposure to a modified market-cap-weighted index of biotechnology and pharmaceutical companies listed on NASDAQ. BIB was launched on Apr 8, 2010 and is managed by ProShares.

Asset Class Equity
Sector Biotech
Region North America
Stock Exchange NASDAQ
Ticker Symbol BIB
Issuer Website ProShares
Index Tracked NASDAQ / Biotechnology

Top 10 Holdings

144.07% of assets
Name Symbol Weight
NASDAQ BIO INDEX SWAP BNP n/a 27.06%
NASDAQ BIOTECHNOLOGY INDEX SWAP GOLDMAN SACHS INTERNATIONAL n/a 22.95%
NASDAQ BIOTECHNOLOGY INDEX SWAP SOCIETE GENERALE n/a 21.01%
NASDAQ BIOTECHNOLOGY INDEX SWAP UBS AG n/a 18.31%
NASDAQ BIOTECHNOLOGY INDEX SWAP BANK OF AMERICA NA n/a 15.60%
NASDAQ BIOTECHNOLOGY INDEX SWAP CITIBANK NA n/a 13.57%
Gilead Sciences, Inc. GILD 7.69%
Amgen Inc. AMGN 6.51%
Vertex Pharmaceuticals, Inc. VRTX 5.69%
Regeneron Pharmaceuticals, Inc. REGN 5.68%
View More Holdings

News

Top Performing Leveraged/Inverse ETFs: 08/07/2022

Top Performing Levered/Inverse ETFs Last Week These were last week's top-performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.

4 months ago - ETF Trends

Cap-Weighting Crucial When Indexing Biotech

The biotechnology industry is a bifurcated space. In one corner, you have nascent, small-cap companies that don't yet have steady revenue streams because their new drug or treatment is still in developm...

Other symbols: BISIBBQ
11 months ago - ETF Trends

How to Invest in Biotech in 2022

It's been a hard year for a lot of the biotech industry, with many hedge funds ending the year with significant losses, but there have been a number of shining stars that are expected to continue to off...

1 year ago - ETF Trends

Take a Look at the Top-Performing Biotech ETFs YTD

The pandemic has triggered a race to introduce vaccines and treatment options, opening up investment opportunities in the biotech sector.

Other symbols: BBHIBBIDNA
1 year ago - Zacks Investment Research

Could Biotech ETFs Get Another Boost From JNJ News?

This has been a pivotal week for biotech news, as Johnson & Johnson said Wednesday that a booster shot of its COVID-19 vaccine generated a promising immune response in early stage clinical trials. This ...

Other symbols: PBE
1 year ago - ETF Trends

Tap the Red Hot Biotech Sector With These 2 Leveraged ETFs

Investors could easily tap the bullish trend by considering a near-term long on the biotech sector.

Other symbols: LABU
1 year ago - Zacks Investment Research

Pfizer-BioNTech COVID-19 Vaccine Garners Full FDA Approval

The FDA has officially given full approval to Pfizer and BioNTech for their COVID-19 vaccine, potentially making way for more approvals and more vaccine mandates, reports CNBC. It is a move that officia...

Other symbols: BNTXPFE
1 year ago - ETF Trends

Biotech ETFs Are Already Benefitting from Pfizer Vaccine's Full Approval

There could be big gains ahead for biotech ETFs, as the Food and Drug Administration on Monday fully approved the Pfizer and BioNTech coronavirus vaccine, making it the first vaccine in the U.S. to be a...

Other symbols: PBE
1 year ago - ETF Trends

As Covid Cases Mutate, the Biotech Industry Works to Keep Up

As the Delta variant sweeps across the globe, pharmaceutical and biotech companies are working to ensure vaccines continue to cover the population, as well as working on booster doses that can adapt to ...

1 year ago - ETF Trends

Top-Performing Biotechnology ETFs Amid Coronavirus Outbreak

From vaccine-related progress to development of cell therapies for the treatment of coronavirus, all kept the rally in the biotech sector alive.

Other symbols: ARKGIDNAXBI
2 years ago - Zacks Investment Research

4 Best-Performing Leveraged ETF Areas of Last Week

Last week witnessed a tug-of-war between bulls and bears.

2 years ago - Zacks Investment Research